Speaker: Edward Nabrinsky, MD, Hematology/Oncology Fellow, Advocate Lutheran General Hospital

Journal Articles:

  1. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, doubleblind, placebo-controlled, phase 3 trial
  2. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Session date: 
08/31/2023 - 8:00am to 9:00am CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
    Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
    Attendance Credit

Please login or register to take this course.